CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today…
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Share this article
More News
Bessent says Iran crypto seizure hits $500 million
April 30, 2026
Sluggish Crypto Markets Struggle to Gain Momentum
April 30, 2026
What are these crypto kiosks Minnesota could soon ban?
April 30, 2026
